Lionel Bosquée - Concepedia

Author

Lionel Bosquée

Centre Hospitalier Universitaire de Liège

Also Known As

L Bosquee, L Bosquée, L. Bosquee, L. Bosqueé, L. Bosquée, Lionel Bosquee, Lionel Bosquée, lionel Bosquee

Publications

1.5K

Citations

H-Index

Concepts

All Affiliations

Centre Hospitalier Universitaire de Liège Ghent University Hospital Centre hospitalier régional de la Citadelle Erasmus Hospital UCLouvain

About

Lionel Bosquée is an author at Centre Hospitalier Universitaire de Liège specializing in medicine, lung cancer, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	12	1K
2	Health Sciences	5	5	668
3	Pharmacology	5	5	649
4	Immunology	4	4	282
5	Pathology	2	2	130

Lionel Bosquée

Publications

1.4K

Citations

H-Index

Page 1

	Year	Citations
Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial Charles Butts, Mark A. Socinski, Paul Mitchell, The Lancet Oncology OncologyMedicineMetronomic TherapyClinical TrialsPharmacotherapy	2013	520
Diagnostic Performance of Soluble Mesothelin and Megakaryocyte Potentiating Factor in Mesothelioma Kevin Hollevoet, Kristiaan Nackaerts, J. Thimpont, American Journal of Respiratory and Critical Care Medicine	2010	95
Increased IL-6 and TGF-β1 concentrations in bronchoalveolar lavage fluid associated with thoracic radiotherapy Nicole Barthelemy-Brichant, Lionel Bosquée, Didier Cataldo, International Journal of Radiation OncologyBiologyPhysics InflammationRadiation MedicineInflammatory Lung DiseaseLung InflammationTgf-β1 Concentrations	2004	93
Soluble Mesothelin, Megakaryocyte Potentiating Factor, and Osteopontin as Markers of Patient Response and Outcome in Mesothelioma Kevin Hollevoet, Kristiaan Nackaerts, Robert C. Gosselin, Journal of Thoracic Oncology SclerostinBone Morphogenic ProteinMegakaryocyte Potentiating FactorImmunologyPathology	2011	82
Safety and Immunogenicity of MAGE-A3 Cancer Immunotherapeutic with or without Adjuvant Chemotherapy in Patients with Resected Stage IB to III MAGE-A3-Positive Non-Small-Cell Lung Cancer Jean-Louis Pujol, Johan Vansteenkiste, Tommaso Martino De Pas, Journal of Thoracic Oncology	2015	60
START: A phase III study of L-BLP25 cancer immunotherapy for unresectable stage III non-small cell lung cancer. Charles Butts, Mark A. Socinski, Paul Mitchell, Journal of Clinical Oncology MedicineImmunologyClinical TrialsStage Iii NsclcImmune Surveillance	2013	59
Multiple Courses of High-Dose Ifosfamide, Carboplatin, and Etoposide With Peripheral-Blood Progenitor Cells and Filgrastim for Small-Cell Lung Cancer: A Feasibility Study by the European Group for Blood and Marrow Transplantation Serge Leyvraz, Lucien Perey, Giovanni Rosti, Journal of Clinical Oncology	1999	57
A multicenter, randomized phase III study of docetaxel + cisplatin (DC) vs docetaxel + carboplatin (DCb) vs vinorelbine + cisplatin (VC) in chemotherapy-naive patients (Pts) with advanced and metastatic non-small cell lung cancer (NSCLC) Chandra P. Belani, Joel Veas Rodríguez, Joachim von Pawel, Lung Cancer MedicineMetronomic TherapyBronchial NeoplasmPhase Iii StudyCancer Treatment	2000	54
Randomized phase III trial of amrubicin versus topotecan (Topo) as second-line treatment for small cell lung cancer (SCLC). Robert M. Jotte, Joachim von Pawel, David R. Spigel, Journal of Clinical Oncology	2011	49
The Effect of Clinical Covariates on the Diagnostic and Prognostic Value of Soluble Mesothelin and Megakaryocyte Potentiating Factor Kevin Hollevoet, Kristiaan Nackaerts, Olivier Thas, CHEST Journal Clinical CovariatesPrognostic ValueHematologyImmunologyPathology	2011	48

Page 1